EcPLA


EcPLA, also known as N-ethyl-N-cyclopropyllysergamide, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide. It is an isomer of LSZ and is closely related to other amide-substituted lysergamides like MiPLA. The drug has been encountered as a novel designer drug.

Use and effects

EcPLA produces psychedelic effects in humans.

Pharmacology

Pharmacodynamics

EcPLA has been found to interact with serotonin receptors and dopamine receptors, among other targets. It is a potency agonist of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors.
The drug produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. It has about 40% of the potency of LSD in this regard.

Pharmacokinetics

The in-vitro metabolism of EcPLA has been studied.

Chemistry

Analogues

Analogues of EcPLA include MiPLA, LAMPA, EPLA, EiPLA, ETFELA, and LSZ, among others.

History

EcPLA was first described in the scientific literature by a team that included Adam Halberstadt, Alexander Stratford, Jason Wallach, and David E. Nichols in 2019. It was developed by Lizard Labs. The drug was encountered online as a novel designer drug in around 2020 and became more widely available in early 2022.